Food and Drug Amanda b will speedily approve Xience, which is now wresting European market share from rival stents such as Johnson amp. Analyst Glenn Novarro said in a research report. Container li a hover color FC. Com i msnbc Components Art SITEWIDE newLogo half. CoverSpat li a visited color DEF. Vascular products, including Xience, jumped percent to million.

Novarro, who predicted Xience will be introduced in the United States in the second quarter of, said the recent sell off of Abbott shares presents a buying opportunity for investors. Growth was fueled by demand for Humira, HIV treatment Kaletra, TriCor to reduce blood fats called triglycerides, and cholesterol treatment Niaspan, which Abbott acquired in its recent purchase of Kos Cheap loan uk.

Sales of prescription drugs rose almost percent to. Analysts, on average, expected cents per share, according to Reuters Estimates. Fl color promo padding top px. Fl color promo a img, fl color promo img border noneimportant. Abbott’s quarterly charges included million for a contract termination and other litigation and a million charge for cost reduction initiatives. Billion, about million higher than Wall Street forecasts.

The drug could get a further boost if its current marketing How addictive is methamphetamine to treat psoriasis is approved. Sales of Depakote, used to treat epilepsy and bipolar disorder, rose percent to million. But sales of Synthroid, a thyroid hormone replacement drug, fell almost percent to million amid stiffer competition from rival products.

Com i msnbc Components Art SITEWIDE coverSpat test. Based on current trends, Abbott said it expects full year earnings of.

Percent in morning New York Stock Exchange trading before slipping in the F10 film finepix fuji, amid moderate gains for the drug sector. Kaletra jumped percent to million, while Tricor sales grew almost percent to million. Excluding special items, Abbott earned cents per share. Abbott Profit Flat as Charges Take Toll. Abbott’s array of products used to diagnose diseases had quarterly sales of million, up almost percent, although U. While the stock has come under pressure as investors worry about a potential delay in the approval of Xience, we continue to project a favorable FDA panel review on Nov.

Shares have fallen more than percent since early October amid worries whether the U. Per share, in line with its earlier forecast, and reaffirmed it expects an accelerating rate of profit growth next year. Billion, with strong trends seen in both U. .

Around the: Online Pharmacy, Cheap Pills.

This entry was posted on Thursday, April 10th, 2008 at 8:31 am and is filed under Cost synthroid. You can follow any responses to this entry through the RSS 2.0 feed. You can skip to the end and leave a response. Pinging is currently not allowed.